Avacta partners with Tempus to enable AI-driven drug development
(Alliance News) - Avacta Group PLC on Monday revealed it has agreed to collaborate with AI-focused precision medicine business, Tempus AI Inc, to optimise its clinical development process and enable "the highest probability of success". Read More